Curing HCV in Incarcerated Patients (CHIP) is a 1-year demonstration project that will assess
the feasibility of a HCV treatment program in the San Francisco City & County Jail. The Jail
Health Services will treat 100 patients using the FDA approved combination treatment,
sofosbuvir/velpatasvir, Epclusa® and will continue their treatment during incarceration and
after their release (if applicable).
Phase:
Phase 4
Details
Lead Sponsor:
San Francisco Department of Public Health
Collaborators:
Gilead Sciences Gilead, Inc. Investigator Sponsored Research San Francisco Study Center University of California, San Francisco